Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.

Issue 14, 2018
Previous Article Next Article

An enzymatic advance in nicotine cessation therapy

Author affiliations


A nicotine-degrading enzyme termed NicA2 was altered (NicA2-J1) through fusion of an albumin binding domain to increase its half-life. Examination of NicA2-J1 in vivo demonstrated a complete blockade of brain nicotine access, which in turn blunted nicotine's psychoactive effects. These data further support development of pharmacokinetic nicotine cessation therapeutics.

Graphical abstract: An enzymatic advance in nicotine cessation therapy

Back to tab navigation

Supplementary files

Article information

28 Nov 2017
28 Dec 2017
First published
02 Jan 2018

Chem. Commun., 2018,54, 1686-1689
Article type

An enzymatic advance in nicotine cessation therapy

S. Xue, M. Kallupi, B. Zhou, L. C. Smith, P. O. Miranda, O. George and K. D. Janda, Chem. Commun., 2018, 54, 1686
DOI: 10.1039/C7CC09134F

Social activity

Search articles by author